natalizumab
biogen
['natalizumab']
found that ahsct was not superior to natalizumab in reducing disability progression, facilitating reduction of disability, or preventing relapses #ectrims2022 
Believe that research can improve our world. An advocate for equity, inclusion and social justice. Currently focused on accelerating research in #MS.